Current Hematologic Malignancy Reports最新文献_第5页

NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition. NK细胞治疗血液系统恶性肿瘤：从潜在到结果。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-09-26 DOI: 10.1007/s11899-023-00711-w

Stephanie L Fetzko, Leander D Timothy, Robin Parihar

{"title":"NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.","authors":"Stephanie L Fetzko, Leander D Timothy, Robin Parihar","doi":"10.1007/s11899-023-00711-w","DOIUrl":"10.1007/s11899-023-00711-w","url":null,"abstract":"Purpose of review: The current review focuses on the preclinical development and clinical advances of natural killer (NK) cell therapeutics for hematologic malignancies and offers perspective on the unmet challenges that will direct future discovery in the field.Recent findings: Approaches to improve or re-direct NK cell anti-tumor functions against hematologic malignancies have included transgenic expression of chimeric antigen receptors (CARs), administration of NK cell engagers including BiKEs and TriKEs that enhance antibody-dependent cellular cytotoxicity (ADCC) by co-engaging NK cell CD16 and antigens on tumors, incorporation of a non-cleavable CD16 that results in enhanced ADCC, use of induced memory-like NK cells alone or in combination with CARs, and blockade of NK immune checkpoints to enhance NK cytotoxicity. Recently reported and ongoing clinical trials support the feasibility and safety of these approaches. NK cell-based therapeutic strategies hold great promise as cost-effective, off-the-shelf cell therapies for patients with relapsed and refractory hematologic diseases.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"264-272"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41110633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders. T细胞淋巴瘤和淋巴增生性疾病分类的最新进展。

IF 2.7 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-10-23 DOI: 10.1007/s11899-023-00712-9

Naoki Oishi, Reham Ahmed, Andrew L Feldman

{"title":"Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.","authors":"Naoki Oishi, Reham Ahmed, Andrew L Feldman","doi":"10.1007/s11899-023-00712-9","DOIUrl":"10.1007/s11899-023-00712-9","url":null,"abstract":"Purpose of review: Mature T/NK-cell neoplasms comprise a heterogeneous group of diseases with diverse clinical, histopathologic, immunophenotypic, and molecular features. A clinically relevant, comprehensive, and reproducible classification system for T/NK-cell neoplasms is essential for optimal management, risk stratification, and advancing understanding of these diseases. Two classification systems for lymphoid neoplasms were recently introduced: the 5th edition of World Health Organization classification (WHO-HAEM5) and the 2022 International Consensus Classification (ICC). In this review, we summarize the basic framework and updates in the classification of mature T/NK-cell neoplasms.Recent findings: WHO-HAEM5 and ICC share basic concepts in classification of T/NK-cell neoplasms, emphasizing integration of clinical presentation, pathology, immunophenotype, and genetics. Major updates in both classifications include unifying nodal T-follicular helper-cell lymphomas into a single entity and establishing EBV-positive nodal T/NK-cell lymphoma as a distinct entity. However, some differences exist in taxonomy, terminology, and disease definitions. The recent classifications of mature T/NK-cell neoplasms are largely similar and provide new insights into taxonomy based on integrated clinicopathologic features.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"252-263"},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10834031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49689167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions. 测量端粒长度的实验和计算方法：最新进展和未来方向。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-11-10 DOI: 10.1007/s11899-023-00717-4

Alejandro Ferrer, Zachary D Stephens, Jean-Pierre A Kocher

{"title":"Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions.","authors":"Alejandro Ferrer, Zachary D Stephens, Jean-Pierre A Kocher","doi":"10.1007/s11899-023-00717-4","DOIUrl":"10.1007/s11899-023-00717-4","url":null,"abstract":"Purpose of review: The length of telomeres, protective structures at the chromosome ends, is a well-established biomarker for pathological conditions including multisystemic syndromes called telomere biology disorders. Approaches to measure telomere length (TL) differ on whether they estimate average, distribution, or chromosome-specific TL, and each presents their own advantages and limitations.Recent findings: The development of long-read sequencing and publication of the telomere-to-telomere human genome reference has allowed for scalable and high-resolution TL estimation in pre-existing sequencing datasets but is still impractical as a dedicated TL test. As sequencing costs continue to fall and strategies for selectively enriching telomere regions prior to sequencing improve, these approaches may become a promising alternative to classic methods. Measurement methods rely on probe hybridization, qPCR or more recently, computational methods using sequencing data. Refinements of existing techniques and new approaches have been recently developed but a test that is accurate, simple, and scalable is still lacking.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"284-291"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10709248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72013872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EBV Reactivation and Lymphomagenesis: More Questions than Answers. EBV 再激活与淋巴致病：问题多于答案。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-08-11 DOI: 10.1007/s11899-023-00708-5

Maegan Ford, Evelyn Orlando, Jennifer Effie Amengual

{"title":"EBV Reactivation and Lymphomagenesis: More Questions than Answers.","authors":"Maegan Ford, Evelyn Orlando, Jennifer Effie Amengual","doi":"10.1007/s11899-023-00708-5","DOIUrl":"10.1007/s11899-023-00708-5","url":null,"abstract":"Purpose of review: Epstein-Barr Virus (EBV) is a ubiquitous herpesvirus that affects almost all humans and establishes lifelong infections by infecting B-lymphocytes leading to their immortalization. EBV has a discrete life cycle with latency and lytic reactivation phases. EBV can reactivate and cause lymphoproliferation in both immunocompetent and immunocompromised individuals. There is sparse literature on monitoring protocols for EBV reactivation and no standardized treatment protocols to treat EBV-driven lymphoproliferation.Recent findings: While there are no FDA-approved therapies to treat EBV, there are several strategies to inhibit EBV replication. These include immunosuppression reduction, nucleoside analogs, HDAC inhibitors, EBV-specific cytotoxic T-lymphocytes (CTLs), and monoclonal antibodies, such as rituximab. There is currently an open clinic trial combining the use of a HDAC inhibitor, nanatinostat, and ganciclovir to treat refractory/relapsed EBV lymphomas. Another novel therapy includes tabelecleucel, which is an allogenic EBV-directed T-cell immunotherapy that was approved by the European Medicines Agency, but is currently only available in the US for limited use in relapsed or refractory EBV-positive PTLD. Further research is needed to establish EBV monitoring protocols in high-risk populations, such as those with autoimmune disease, cancer, HIV, or receiving immunosuppressive therapy. Additionally, standardized treatments for both the prevention of EBV reactivation in high-risk populations and treatment of EBV reactivation and lymphoproliferation need to be established.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"226-233"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9974900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. 晚期慢性髓性白血病管理的最新进展。

IF 2.7 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-08-31 DOI: 10.1007/s11899-023-00709-4

Nicholas J Short, Jayastu Senapati, Elias Jabbour

引用次数: 0

Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders. 端粒生物学障碍患者的遗传咨询和家庭筛查建议。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-10-03 DOI: 10.1007/s11899-023-00713-8

Laura Ongie, Hannah A Raj, Katie Barrett Stevens

引用次数: 0

Central Nervous System Relapse in T and NK cell Lymphomas. T 细胞和 NK 细胞淋巴瘤的中枢神经系统复发。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-08-25 DOI: 10.1007/s11899-023-00710-x

Eleanor P Taranto, Stefan K Barta, Rahul S Bhansali

{"title":"Central Nervous System Relapse in T and NK cell Lymphomas.","authors":"Eleanor P Taranto, Stefan K Barta, Rahul S Bhansali","doi":"10.1007/s11899-023-00710-x","DOIUrl":"10.1007/s11899-023-00710-x","url":null,"abstract":"Purpose of review: T and NK cell lymphomas are relatively rare and heterogeneous forms of non-Hodgkin lymphoma that are associated with high rates of mortality. Central nervous system relapse carries significant morbidity, though management is largely extrapolated from literature in B cell neoplasms. As such, outcomes for central nervous system involvement in T/NK cell lymphomas are dismal with no standard of care. In this review, we discuss the epidemiology of central nervous system relapse in T/NK cell lymphomas and critically analyze available literature regarding prophylaxis and treatment.Recent findings: Retrospective studies of central nervous system involvement in T/NK cell lymphomas have been limited by small sample sizes and heterogeneity of subtypes, though sites of extranodal involvement and disease subtypes are consistently reported as risk factors. Compelling evidence for the use of central nervous system-directed prophylactic therapy has not yet been established, though recent reports of central nervous system activity with novel agents may suggest promising therapeutic options. The overall rarity of T and NK cell lymphomas has precluded adequate study of prophylaxis and treatment of central nervous system relapse. Collaborative efforts are needed to better define strategies to address CNS disease in T/NK cell lymphomas. These should involve the use of targeted agents, which may hold an advantage over traditional cytotoxic drugs.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"243-251"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10058085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measurable Residual Disease Monitoring in Lymphoma. 淋巴瘤可测量残留疾病监测。

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-11-06 DOI: 10.1007/s11899-023-00715-6

Brian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng

{"title":"Measurable Residual Disease Monitoring in Lymphoma.","authors":"Brian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng","doi":"10.1007/s11899-023-00715-6","DOIUrl":"10.1007/s11899-023-00715-6","url":null,"abstract":"Purpose of review: The utility of analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and disease in the bone marrow as an adjunctive tool in caring for hematologic cancer patients is expanding. This holds true for lymphoma where these biomarkers are being explored as a means of genotyping and quantifying disease. Regarding the latter, they can be used to monitor measurable residual disease (MRD) during and after treatment. This holds potential for aiding clinical decisions amidst treatment, detecting earlier relapse, and improving prognostication. Here, we review the evidence to support these applications in a variety of lymphoma subtypes.Recent findings: Numerous clinical trials across a variety of lymphomas have demonstrated value in MRD monitoring. MRD monitoring is often prognostic for progression free survival (PFS) and even overall survival (OS) at several time points in a disease course, particularly when utilizing serial measurements. With regards to tailoring treatment, there are a growing number of trials examining MRD-adaptive treatment strategies to intensify or de-escalate treatment to individualize care. Lastly, MRD monitoring has been utilized successfully in detecting earlier relapse when compared to more standard methods of clinical surveillance such as radiographic assessment. Although not routinely implemented into clinical practice, MRD monitoring in lymphoma is helping shape the future landscape of this disease by aiding in prognostication, guiding therapy, and detecting earlier relapse. Steps to standardize and further examine this technology prospectively are being taken to bring MRD monitoring to the forefront of the field.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"292-304"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. 开发针对 T 细胞急性淋巴细胞白血病/淋巴瘤的靶向疗法。

IF 2.7 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-12-01 Epub Date: 2023-07-25 DOI: 10.1007/s11899-023-00706-7

Adam S DuVall, Austin Wesevich, Richard A Larson

引用次数: 0

Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress? 慢性淋巴细胞白血病的Richter转化我们正在取得进展吗？

IF 2.9 3区医学

Current Hematologic Malignancy Reports Pub Date : 2023-10-01 Epub Date: 2023-06-09 DOI: 10.1007/s11899-023-00701-y

Hadiyah Y Audil, Samuel R Kosydar, Daniel P Larson, Sameer A Parikh

{"title":"Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?","authors":"Hadiyah Y Audil, Samuel R Kosydar, Daniel P Larson, Sameer A Parikh","doi":"10.1007/s11899-023-00701-y","DOIUrl":"10.1007/s11899-023-00701-y","url":null,"abstract":"Purpose of review: The treatment paradigm of chronic lymphocytic leukemia (CLL) has dramatically changed with the advent of novel targeted agents over the past decade. Richter transformation (RT), or the development of an aggressive lymphoma from a background of CLL, is a well-recognized complication of CLL and carries significantly poor clinical outcomes. Here, we provide an update on current diagnostics, prognostication, and contemporary treatment of RT.Recent findings: Several genetic, biologic, and laboratory markers have been proposed as candidate risk factors for the development of RT. Although a diagnosis of RT is typically suspected based on clinical and laboratory findings, tissue biopsy is essential for histopathologic confirmation of diagnosis. The standard of care for RT treatment at this time remains chemoimmunotherapy with the goal of proceeding to allogeneic stem cell transplantation in eligible patients. Several newer treatment modalities are being studied for use in the management of RT, including small molecules, immunotherapy, bispecific antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy. The management of patients with RT remains a challenge. Ongoing trials show enormous promise for newer classes of therapy in RT, with the hope being that these agents can synergize, and perhaps supersede, the current standard of care in the near future.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"18 5","pages":"144-157"},"PeriodicalIF":2.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10167407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1